These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Anti-tumor necrosis factor-alpha therapy provokes latent leishmaniasis in a patient with rheumatoid arthritis. Franklin G; Greenspan J; Chen S Ann Clin Lab Sci; 2009; 39(2):192-5. PubMed ID: 19429808 [TBL] [Abstract][Full Text] [Related]
12. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results. Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981 [TBL] [Abstract][Full Text] [Related]
13. Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor. Marotte H; Arnaud B; Diasparra J; Zrioual S; Miossec P Arthritis Rheum; 2008 May; 58(5):1258-63. PubMed ID: 18438841 [TBL] [Abstract][Full Text] [Related]
14. Increase in plasma levels of adiponectin after administration of anti-tumor necrosis factor agents in patients with rheumatoid arthritis. Nagashima T; Okubo-Fornbacher H; Aoki Y; Kamata Y; Kimura H; Kamimura T; Nara H; Iwamoto M; Yoshio T; Okazaki H; Minota S J Rheumatol; 2008 May; 35(5):936-8. PubMed ID: 18464318 [No Abstract] [Full Text] [Related]
15. Emerging biologic drugs for the treatment of rheumatoid arthritis. Puppo F; Murdaca G; Ghio M; Indiveri F Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092 [TBL] [Abstract][Full Text] [Related]
16. Combined tumour necrosis factor-alpha and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients' response to anti-TNF-alpha therapy and explain controversies of studies based on a single polymorphism. Chatzikyriakidou A; Georgiou I; Voulgari PV; Venetsanopoulou AI; Drosos AA Rheumatology (Oxford); 2007 Jun; 46(6):1034-5. PubMed ID: 17409133 [No Abstract] [Full Text] [Related]
17. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559 [TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor-alpha blockade and the risk of vasculitis. Guillevin L; Mouthon L J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348 [No Abstract] [Full Text] [Related]